Condition
AIHA - Warm Autoimmune Hemolytic Anemia
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Recruiting3
Unknown1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07530380Early Phase 1RecruitingPrimary
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07083960Phase 1RecruitingPrimary
OM336 in Autoimmune Cytopenias
NCT07019038RecruitingPrimary
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
NCT06847607Not ApplicableNot Yet RecruitingPrimary
A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
NCT03827603Phase 2UnknownPrimary
Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia
Showing all 5 trials